SALT LAKE CITY, Oct. 6, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia. Data will be presented on MPI-0485520, a potent and selective oral anti-interferon (OAI) in preclinical development. MPI-0485520 targets I kappa B kinase epsilon (IKK epsilon) and TANK-binding kinase 1 (TBK1), which are required for the initiation of certain inflammatory immune responses involving type-I interferons (IFN alpha/beta).
|Title:||Inhibition of Cytosolic Nucleic Acid Receptor|
|Pathways Using the Small Molecule IKK|
|epsilon/TBK1 Kinase Inhibitor MPI-0485520|
|Date & Time:||Monday, November 08, 2010; 9 AM - 6 PM|
For more information, please visit www.myrexis.com .The Myrexis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6327 Forward-looking statement safe harbor This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and potential efficacy of Myrexis' product candidate MPI-0485520. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to, the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2010, which was filed with the Securities and Exchange Commission on September 13, 2010, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.
CONTACT: Myrexis, Inc. Patrick M. Burke, Ph.D., V.P., Corporate and Business Development 801-214-7822 firstname.lastname@example.org The Ruth Group Investors Sara Pellegrino (646) 536-7002 email@example.com Media Jason Rando (646) 536-7025 firstname.lastname@example.org